Antimicrobial resistance is a top public health concern globally. Cefiderocol, a recently approved siderophore cephalosporin antimicrobial, will be evaluated using a case series and literature review. Join us to learn when to use the newest cephalosporin in patient care.

Upon successful completion of this application-based course, pharmacists and students should be able to:
1. Describe the mechanism of action for cefiderocol
2. Contrast the antimicrobial spectrum between cefiderocol and carbapenems
3. Discuss the results and conclusions of a recent article
4. Define statistical tools for literature evaluation, like non-inferiority margin
5. Propose clinical appropriateness for cefiderocol in stewardship programs

Christina Rivera, PharmD, BCPS, AAHIV-P
Pharmacist
Mayo Clinic Rochester

Christina Rivera does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course. 

This month’s Journal Club is supported by an educational grant from Xellia Pharmaceuticals, a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections.

CEimpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read:

Zingg S, Nicoletti GJ, Kuster S, et al. Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature. Open Forum Infectious Diseases. May 2020.

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Initial Release Date: November 11, 2020
Planned Expiration Date: November 11, 2023